La 6ª convocatoria del 7PM - Salud

Transcripción

1 La 6ª convocatoria del 7PM - Salud Salamanca, 12 de junio de 2011 Jornada de Presentación de la 6ª Convocatoria de Salud del VII Programa Marco Juan E. Riese SGPIIRI Oficina de Proyectos Europeos 1

2 La presentación La 6ª convocatoria FP7 Salud Algunos consejos para la elaboración de propuestas (coordinadas) 2

3 Drivers for FP7 from Innovation Union policy Innovation-driven approach Focus on SMEs through genuine academia-industry collaborations Challenge-driven approach, focussed on key challenges Support implementation of European Innovation Partnerships, such as Active and healthy ageing Stronger socio-economic impact - innovation dimension with more attention on exploitation phase Balance upstream research and activities closer to market in order to achieve short and medium-term impact 3

4 Features of FP7 Health in 2012 Indicative budget for 2012 calls: 650m (to be confirmed) 2 Health calls: FP7-HEALTH-2012-INNOVATION-1 (33 topics, 540m) FP7-HEALTH-2012-INNOVATION-2 ( 3 topics, 108m) FP ERA-NET call (1 topic, 2m) ALL topics (but one) will have two-stage submission MOST topics (29/37) can have several projects funded (exceptions: 6 CSA, 1 IP, PLC with Australia) 15 SME-targeted topics (including special call, 15-50% budget) plus 2 Industry-targeted topics (including SMEs) A special action for the preparation of EDCTP-2 4

5 Priorities of FP7 Health in 2012 Main priorities: Ageing will be the 1st priority in 2012 budget ~ 220m (incl. med. tech, biomarkers, clinical trials, co-morbidity, health services) Medical technologies 160m Rare diseases ~ 100m SME targeted actions: 3 topics: 50% EC contrib. to SMEs: 108m 6 topics: 30% EC contrib. to SMEs: 180m 6 topics: 15% EC contrib. to SMEs: 72m Total: 15 topics (out of 37 topics) 360m (~55%) NB: total budget: 650m (some overlap between priorities & budgets) 5

6 New initiative SMEs for Innovation call (1) (INNOVATION-2) Pilot initiative to stimulate innovation via enhanced SME participation 3 broad topics with a focus on medical technologies: Medical technology for transplantation and bio-artificial organs Diagnostics for infectious diseases (in humans) Technological approaches to combating sensory impairment 6

7 New initiative SMEs for Innovation call (2) (INNOVATION-2) Pilot initiative to stimulate innovation via enhanced SME participation Special conditions: 3-5 partners, min. 50% of req. EU funding for SME(s) Restricted to entities from EU and Associated Countries max. 3 years The SME must have a leading role in the project 2-stage submission & evaluation Simplified application process: short project description Accelerated procedures for submission, evaluation & negotiation i.e.: earlier deadlines for 1 st and 2 nd stage submission. 7

8 Cambios adicionales en la 6ª convocatoria 8

9 General conditions 2012 Any research organisation can participate, including larger companies, as well as service-providers. However, the funding levels are different: For SMEs: 75% of research costs (+ 100% management & training & eligible IP costs) For larger companies: 50% of research costs (+ 100% management & training & eligible IP costs) What is an SME? (for the EC: ) 1. less than 250 employees 2. annual turnover 50 million OR balance sheet total 43 million 3. must be autonomous* * check SME status: 9

10 Funding schemes for FP7 Health in 2012 Funding scheme Ceiling for EU contribution Number of topics % budget Large-scale integrating project (CP-IP) 12m 4 ~ 16.5% Small or medium scale focused project (CP-FP) 3m / 6m 24 ~ 78% Coordinating or supporting action (CSA) various 9 ~ 2.5% Other actions* various ~ 2% Total % * including HFSPO, EDCTP, study on emerging areas for research/innovation, study on impact of ethics review on health research, production of videos. 10

11 Calls for FP7-HEALTH-2012-Innovation-1 FP7-HEALTH-2012-Innovation-2 Proposal scoring: Each criterion is scored 0-5 half-scores allowed Scores must pass thresholds if a proposal is to be considered for funding Thresholds apply to individual criteria stage 1 stage2 S&T Impact total S&T Implementation Impact total Innovation- 1 4/5 3/5 8/10 4/5 3/5 3/5 12/15 Innovation- 2 4/5 4/5 8/10 4/5 3/5 4/5 12/15 11

12 Call deadlines* FP7-HEALTH-2012-Innovation-1 Stage 1 proposals: 04 October 2011 FP7-HEALTH-2012-Innovation-2 Stage 1 proposals: 27 September 2011 *: to be confirmed in calls to be published on CORDIS in July

13 Países que pueden participar 13

14 14

15 Activity 1 Biotech, tools & technologies Detection, diagnosis and monitoring Development of technologies with a view to patient group stratification for personalised medicine applications Funding scheme: CP-FP, SME-topic (min. 30% for SMEs) max. 6m/project. >10 projects to be funded 15

16 Activity 1 Biotech, tools & technologies Innovative therapeutic approaches & interventions Innovative approaches to solid organ transplantation. Funding scheme: CP-FP, SME-topic (min. 15% for SMEs) max. 6m/project, ~3 projects to be funded Medical technology for transplantation and bioartificial organs. [ SMEs for Innovation call ] Funding scheme: CP-FP, SME-topic (min. 50% for SMEs) 3-5 partners, max. 6m/project. 5-7 projects to be funded 16

17 Activity 1 Biotech, tools & technologies Innovative therapeutic approaches & interventions Innovative strategies for translation of stem cell based therapies in regenerative medicine (EU-Australia cooperation) Funding scheme: CP-FP, SME-topic (min. 15% for SMEs) max 6m/project, max 1 project to be funded Targeted nucleic acid delivery as an innovative therapeutic or prophylactic approach. Funding scheme: CP-FP, Industry-topic (min. 30% for industry, including SMEs); max 6m/project, ~3 projects to be funded 17

18 Activity 2. Translating research for human health Area 2.1 Integrating biological data & processes Large-scale data gathering A Support for international rare diseases research.! Funding scheme: SA, max. 2m/project, max. 1 project B Clinical utility of -omics for better diagnosis of rare diseases. Funding scheme: CP-IP, SME-topic (min. 30% for SMEs); max. 12m/project, max. 2 projects C Databases, biobanks rare diseases research. Funding scheme: CP-IP, max. 12m/project, max. 1 project 18

19 Area 2.1 Integrating biological data & processes Large-scale data gathering Validation of -omics based biomarkers for diseases affecting the elderly Funding scheme: CP-IP, SME-topic (min. 30% for SMEs) max. 12m/project, up to ~2-3 projects Statistical methods for collection and analysis of -omics data. Funding scheme: CP-FP, SME-topic (min. 15% for SMEs) max. 6m/project, ~1 project to be funded 19

20 Area 2.1 Integrating biological data and processes Systems Biology Systems medicine: SME-driven research applying systems biology approaches to address medical & clinical needs Funding scheme: CP-FP, SME-topic (min. 30% for SMEs) max. 3m/project, up to 6-8 projects Systems medicine: applying systems biology approaches for understanding multifactorial human diseases and their co-morbidities. Funding scheme: IP, max. 12m/project, up to ~3-4 projects Preparing for the future research and innovation activities in systems medicine. Funding scheme: CA, max. 3m/project, max. 1 project funded 20

21 Area 2.2 Brain, dev. & ageing Human development and ageing Integrative systems biology and comparative genomics for studying human ageing and/or most common age-related diseases. Funding scheme: CP-FP, SME-topic (min. 30% for SMEs) max. 6m/project. Up to ~3 projects Investigator-driven clinical trials for optimisation of management of elderly patients with multiple diseases. Funding scheme: CP-FP, SME-topic (min. 15% for SMEs) max. 6m/project. Up to ~3 projects 21

22 Area 2.3 Infectious diseases 2.3 Translational research in major infectious diseases Covers major HIV/AIDS, malaria, tuberculosis, hepatitis, neglected infectious diseases, emerging epidemics, fungal pathogens, as well as anti-microbial drug resistance Diagnostics for infectious diseases in humans [ SMEs for Innovation call ] Funding scheme: CP-FP, SME-topic (min. 50% for SMEs) 3-5 partners, max. 6m/project. Up to ~6 projects ERA-NET on infectious diseases [ ERA-NET call ] Funding scheme: CA, max. 2m/project, max. 1 project 22

23 Area 2.3 Infectious diseases HIV/AIDS, malaria and tuberculosis Co-infection of HIV/AIDS, malaria, tuberculosis and/or hepatitis. Funding scheme: CP-FP, max. 6m/project, up to 2-3 projects Co-morbidity between infectious diseases and non-communicable diseases. Funding scheme: CP-FP, max. 6m/project, up to 2-3 projects 23

24 Area 2.3 Infectious diseases HIV/AIDS, malaria and tuberculosis Prevention and treatment for HIV/AIDS, malaria and tuberculosis. Small consortia encouraged (3-5 partners), duration 1-3 years. Funding scheme: CP-FP, SME-topic (min. 15% for SMEs) max. 6m/project, up to 2-3 projects Low-cost interventions for disease control in resource poor settings. Funding scheme: CP-FP, max. 3m/project, up to 3-4 projects Action to support preparation of 2 nd phase of EDCTP Funding scheme: CSA, max. 10m 24

25 Area 2.4 Major diseases Cancer (closed) Cardiovascular diseases (closed) Diabetes and obesity Innovative approaches to manage diabetes. Funding scheme: CP-FP, SME-topic (min. 30% for SMEs) max. 6m/project. Up to 3-4 projects Investigator-driven clinical trials for type 1 diabetes research. Funding scheme: CP-FP, max. 6m/project, up to 2-3 projects 25

26 Area 2.4 Major diseases Rare diseases Preclinical and/or clinical development of substances with a clear potential as orphan drugs. Funding scheme: CP-FP, Industry-topic (min. 30% for industry, including SMEs); max 6m/project, up to ~10 projects Observational trials in rare diseases. Funding scheme: CP-FP, max. 3m/project, ~3-4 projects Best practice and knowledge sharing in the clinical management of rare diseases. Funding scheme: CA, max. 2m/project, max. 1 project 26

27 Area 2.4 Major diseases Chronic diseases Technological approaches to combating sensory impairments. [ SMEs for Innovation call ] Funding scheme: CP-FP, SME-topic (min. 50% for SMEs) 3-5 partners, max. 6m/project. Up to ~5-6 projects Biomarkers and diagnostics for chronic inflammatory diseases of the joints and/or digestive system. Funding scheme: CP-FP, SME-topic (min. 15% for SME) max. 6m/project. Up to ~2 projects 27

28 Optimising delivery of healthcare 3.2 Quality, efficiency and solidarity of healthcare systems Improving the organisation of health service delivery. Funding scheme: CP-FP, max. 3m/project, up to ~7-8 projects New methodologies for health technology assessment Funding scheme: CP-FP, max. 3m/project, up to ~2-3 projects Social innovation for ageing research Funding scheme: CP-FP, max. 3m/project, up to ~1-2 projects 28

29 Optimising delivery of healthcare 3.4 International public health & health systems Research on Health systems and services in low/middle income countries. Projects should generally be 5 years in duration. Min. 6 different ICPC partners & 2 EU/AC partners from different countries. Funding scheme: CP-FP (SICA), max. 6m/project, ~3 projects 29

30 Activity 4. Actions across the Health theme 4.1 CSAs across the theme Network to encourage knowledge transfer activity in FPfunded health research (especially in academic and governmental organisations). Funding scheme:ca, max. 2m/project, up to 1 project Training actions linked to intellectual property rights management and knowledge transfer. Funding scheme:ca, max. 2m/project, up to 1 project 30

31 Activity 4. Actions across the Health theme 4.1 CSAs across the theme (ctd.) Support for presidency events. Organisation of supporting actions and events related to the EU Presidency. Funding scheme: SA, max. 0.1m/project, up to 2-3 projects Communicating the benefits of European research to the general public. Funding scheme: CA, max. 1m/project, up to 1-2 projects Preparing the future for health research and innovation Funding scheme: CSA, max. 0.5m/project, up to 1-2 projects 31

32 Opportunities in other Themes KBBE: complementary to Theme Health KBBE : Role of health-related symbols and claims in consumer behaviour KBBE : Beneficial effects of bioactive compounds in humans KBBE : Study on the needs for food and health research infrastructures KBBE : Impact of lifestyle on well-being and diet-related disease 32

33 Opportunities in other Themes NMP: complementary to Theme Health NMP : Development and phase-i clinical trials of novel therapeutic nanotechnology-enabled systems for the diagnosis and treatment of atherosclerosis NMP : ERA-NET on nanomedicine NMP : Systematic investigations of the mechanisms and effects of engineered nanomaterial interactions with living systems and/or the environment NMP : Modelling toxicity behaviour of engineered nanoparticles NMP : Biomaterials for improved performance of medical implants 33

34 Opportunities in other Themes SSH: complementary to Theme Health ERA-net Coordinating research economic agendas Making longevity an asset for economic and social development A European childhood and youth survey Forward looking tools and methods for answering major societal challenges 34

35 Opportunities in other Themes ICT: complementary to Theme Health ICT Virtual Physiological Human (call 9) a) Patient-specific predictive computer-based models and simulation b) Development of ICT tools, services and infrastructure to obtain more elaborate and reusable multi-scale model d) Early demonstrators and proof of concept of digital representations of health status All other areas of challenge 5: ICT for Health, Ageing Well, Inclusion and Governance are closed in

36 A tener en cuenta en la preparación de las propuestas de proyecto desde el punto de vista del evaluador 36

37 37

38 Contenido de la Guía del Solicitante 38

39 Criterios generales Elegibilidad: Presentación en el plazo exigido Número mínimo de participantes exigido Documentación completa Contenido relativo al tema y esquema de financiación oportuno Límite de presupuesto solicitado correcto Extensión de los documentos 39

40 La evaluación en proyectos de dos fases. 1ª Fase 40

41 La evaluación en proyectos de dos fases. 2ª Fase 41

42 Criterios (I) Criterio 1. Excelencia científica y tecnológica Solidez del concepto y calidad de los objetivos Medida en que la propuesta representa un avance más allá del estado actual de la ciencia y la tecnología Calidad y eficacia de la metodología científico-técnica y del plan de trabajo asociado 42

43 Criterios (II) Criterio 2. Calidad y eficacia de la implementación y de la gestión del proyecto Medida en que la estructura y procedimientos de gestión son adecuados Calidad y experiencia relevante de los participantes individuales Calidad del consorcio en conjunto, incluyendo complementariedad y equilibrio Medida en que la asignación y justificación de los recursos propuestos son adecuados (personal, equipamiento) 43

44 Criterios (III) Criterio 3. Impacto potencial basado en el desarrollo, difusión y utilización de los resultados del proyecto Contribución a nivel europea e internacional del proyecto a los impactos esperados que se especifican en el Programa de Trabajo de la convocatoria Medida en que las acciones propuestas de difusión y explotación de los resultados, así como de gestión de la Propiedad Intelectual son las adecuadas Cuestiones de ética y bioética Cuestiones de género 44

45 Proceso Comisión: Elegibilidad Evaluación individual: On line. Expertos independientes. Confidencialidad. Declaración de conflicto de intereses. Reunión de consenso: Todos los expertos en Bruselas. 3 días: 2 de consenso para ~ 12 proyectos y un día para informes de consenso. Panel de revisión: Orden de prioridad. Mismos evaluadores + otros. 45

46 Proceso Orden de prioridad: Para cada sublínea de presupuesto, según la convocatoria Criterios de priorización: - orden de puntuación - a igual puntuación total, orden de puntuación científico técnica - evitar la priorización de propuestas de contenido similar a las de mayor puntuación - cobertura de todo el programa de trabajo, equilibrio de temas - solo una propuesta para temas large Mínimo para ser financiado 12 puntos 46

47 Baremo de puntuaciones Puntuación de cada criterio y subcriterio: The proposal fails to address the criterion under examination or cannot be judged due to missing or incomplete information 1 - Poor. The criterion is addressed in an inadequate manner, or there are serious inherent weaknesses. 2 - Fair. While the proposal broadly addresses the criterion, there are significant weaknesses. 3 - Good. The proposal addresses the criterion well, although improvements would be necessary. 4 - Very Good. The proposal addresses the criterion very well, although certain improvements are still possible. 5 - Excellent. The proposal successfully addresses all relevant aspects of the criterion in question. Any shortcomings are minor. Umbrales: 3 en cada criterio individual; 10 en conjunto. 47

48 En consecuencia, cómo se debe preparar la propuesta de proyecto? 48

49 Antes de empezar (I) Se necesita una idea innovadora de suficiente envergadura Proyecto pequeño, mediano o grande Coordinador o socio Tener en mente socios adecuados Tener una visión clara de la aplicabilidad de los resultados a obtener EL IMPACTO La dedicación en la preparación de la propuesta para la 1ª fase es menor 49

50 Antes de empezar (II) Pero, el paso crítico (stop or go) es preguntarse: Se ajusta la propuesta de proyecto pensada al texto del Topic y al instrumento exactamente, tal como se encuentra expuesto en la convocatoria abierta? 50

51 Acciones de preparación de propuestas como socio,. Contactos entre investigadores Teléfono y correo electrónico: envío de borradores Reuniones presenciales 51

52 con el objetivo de Establecer el papel de cada socio en el proyecto Consensuar, redactar y firmar acuerdos de confidencialidad Definición de Work packages Reparto e integración de tareas de cada socio Definir y fijar cuestiones de propiedad intelectual Acordar cuestiones relacionadas con explotación de resultados Proceder al desarrollo del presupuesto 52

53 Modus operandi real en la preparación de la propuesta para la 1ª fase Cada socio describirá su parte y la enviará al coordinador: Información suficiente para que el coordinador pueda integrar datos y texto: Información científico-técnica Objetivos Aplicaciones esperadas EL IMPACTO Presupuesto aproximado en la 1ª fase Posibilidad de reuniones físicas y Conferencias Telefónicas 53

54 Partes de una propuesta de proyecto (2ª fase) Formularios (parte A): el coordinador distribuirá los adecuados para los socios (datos, filiación, etc.) Resumen (el coordinador lo redactará al final) Plan de Trabajo (parte B) compuesta por: Objetivos científico-técnicos, y state of the art Relevancia de los objetivos en el marco de la convocatoria Impacto esperado Descripción del consorcio y los recursos Plan de gestión del proyecto Plan de implementación detallado Consideraciones de género, éticas, de propiedad intelectual y de difusión. 54

55 Información útil La ficha de la convocatoria El Programa de Trabajo La guía del solicitante Anexos de información general 55

56 Recomendaciones generales (I) Diseñar un acrónimo y un título del proyecto adecuados El resumen debe cautivar y atraer el interés de un evaluador. Deberá ser escrito al final del proceso de redacción del proyecto. State of the art claro Objetivos, métodos, resultados y entregables sin vaguedades IMPACTO (!) Plan de trabajo bien diseñado: cronograma, complementariedad en el reparto de tareas (2ª fase) Descripción convincente del plan de implementación y explotación de los resultados (2ª fase) Costes realistas El lema fundamental: estilo simple y claro, sin perder calidad 56

57 Recomendaciones generales (II) Redacción en inglés correcto Texto claro, bien estructurado y que se lea con facilidad: Hacerlo visualmente atractivo: párrafos y frases cortas, resaltar los mensajes y conceptos importantes Uso de tipo de escritura agradable Usar gráficos y tablas Pero incluir solamente información relevante Hacer revisar el proyecto a compañeros con espíritu crítico Muy recomendable inscripción como evaluador/a: 57

58 A tener presente en todo momento Estilo de redacción simple y claro, pero sin perder calidad. A tener en cuenta: Los evaluadores no tienen (habitualmente) el mismo grado de experiencia en el área que el solicitante Empezar con mucha antelación e ir salvando en la aplicación telemática lo trabajado 58

59 Muchas gracias La OPE - ISCIII Asesores científicos Teresa Corral Tel.: ; tcorral@isciii.es Juan E. Riese (NCP Salud) Tel.: ; jriese@isciii.es Especialista en cuestiones financieras (NCP) Gonzalo Arévalo Tel.: ; garevalo@isciii.es Especialista en cuestiones legales (NCP-IDEAS) Lucía del Río Tel.: ; ldrio@isciii.es Especialista en relaciones con la CE Marta Barrionuevo Tel.: ; mbarrionuevo@isciii.es Especialista en convocatorias, documentación y boletín Laura Mohedano Tel.: ; lmohedano@isciii.es 59